The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 17, 2020
Filed:
Jun. 05, 2019
Applicant:
Purdue Pharma L.p., Stamford, CT (US);
Inventors:
Benjamin Oshlack, Boca Raton, FL (US);
Curtis Wright, Norwalk, CT (US);
J. David Haddox, Upper Stepney, CT (US);
Assignee:
Purdue Pharma L.P., Stamford, CT (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/14 (2006.01); A61K 9/50 (2006.01); A61K 9/00 (2006.01); A61K 9/02 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 9/70 (2006.01); A61K 9/48 (2006.01); A61K 31/485 (2006.01); A61K 9/51 (2006.01);
U.S. Cl.
CPC ...
A61K 9/5084 (2013.01); A61K 9/006 (2013.01); A61K 9/0043 (2013.01); A61K 9/0053 (2013.01); A61K 9/02 (2013.01); A61K 9/14 (2013.01); A61K 9/1617 (2013.01); A61K 9/1635 (2013.01); A61K 9/1647 (2013.01); A61K 9/1676 (2013.01); A61K 9/1694 (2013.01); A61K 9/2077 (2013.01); A61K 9/2081 (2013.01); A61K 9/2866 (2013.01); A61K 9/4808 (2013.01); A61K 9/50 (2013.01); A61K 9/501 (2013.01); A61K 9/5015 (2013.01); A61K 9/5026 (2013.01); A61K 9/5031 (2013.01); A61K 9/5078 (2013.01); A61K 9/51 (2013.01); A61K 9/7053 (2013.01); A61K 9/7061 (2013.01); A61K 31/485 (2013.01);
Abstract
Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.